New AUA Guideline (2024): Salvage Therapy for Prostate Cancer Webcast (2024)

The course details the 2024 AUA Guidelines for salvage therapy following initial treatment of localized prostate cancer, focusing on integral aspects of salvage treatments, risk stratification and advanced imaging. Participants will gain insights into the timing and appropriate use of salvage radiation therapy with or without androgen deprivation therapy (ADT), the use of risk stratification tools and the application of next-generation imaging in patients with biochemical recurrence. Participants will learn about the latest data supporting optimizing cancer control based on key patient and tumor factors. Key aspects of the course include mastering the interpretation of biomarkers and imaging techniques for accurate detection and monitoring of recurrent prostate cancer. We also emphasize the vital role of shared decision-making in clinical practice, considering patients’ preferences and quality of life. The course aims to equip health care professionals with the necessary knowledge and practical skills to improve patient outcomes in managing recurrent prostate cancer.


This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify and effectively interpret the optimal timing of salvage radiation therapy following radical prostatectomy, considering the factors that can influence this decision in a clinical context.
  2. Develop an understanding of which patients should receive ADT alongside salvage radiation therapy following radical prostatectomy, and how to appropriately decide the duration of ADT for patients.
  3. Identify and analyze the use of risk stratification tools and next-generation imaging techniques for guiding treatment decisions and monitoring in patients with biochemical recurrence following primary therapy.
  4. Evaluate the role and benefits of advanced treatment options such as intensified systemic therapy and metastasis-directed therapy.
  5. Evaluate and understand the indications, efficacy, and potential complications of different salvage local therapies, such as salvage prostatectomy, radiotherapy and cryotherapy, for patients with local recurrence following primary radiation therapy.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Boorjian, Stephen A.FerringConsultant or AdvisorCurrent
ArTaraConsultant or AdvisorCurrent
FerGeneConsultant or Advisor08/01/2023
ProkariumConsultant or AdvisorCurrent
Kamran, Sophia CVARIAN MEDICAL SYSTEMSMeeting Participant or Lecturer07/25/2022
Morgan, Todd MatthewA3P BiomedialMeeting Participant or Lecturer02/16/2023
Foundation MedicineConsultant or AdvisorCurrent
Tagawa, Scott T.JanssenConsultant or Advisor06/28/2023
Medivation/AstellasConsultant or Advisor10/30/2022
LillyScientific Study or TrialCurrent
BristolMyersSquibbScientific Study or TrialCurrent
MerckScientific Study or TrialCurrent
NovartisScientific Study or TrialCurrent
ClarityScientific Study or TrialCurrent
POINT BiopharmaConsultant or Advisor02/28/2023
POINT BiopharmaScientific Study or TrialCurrent
Telix PharmaConsultant or Advisor06/14/2023
GileadScientific Study or TrialCurrent
GileadConsultant or Advisor06/04/2023
BayerConsultant or Advisor06/04/2023
NovartisConsultant or Advisor08/09/2023
RegeneronConsultant or Advisor02/28/2023
Daiichi SankyoConsultant or Advisor02/28/2023
PfizerConsultant or Advisor06/01/2023
Boston ScientificConsultant or AdvisorCurrent
AmbrxConsultant or AdvisorCurrent



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.